A biomarker analysis of plasma and tumor DNA in afatinib-treatedpatients with EGFR mutation-positive advanced adenocarcinoma of the lung.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Jan 2017
At a glance
- Drugs Afatinib (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- Acronyms Afatinib I I S
- 15 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 09 May 2014 New trial record